Zavante CEO sells his late-stage antibiotic biotech to Nabriva — grabbing the helm in the deal
The last time I talked to Zavante CEO Ted Schroeder in the spring of 2017, he was steering his antibiotic Zolyd (fosfomycin for injection …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
